• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Kalvista Pharmaceuticals Inc (NQ: KALV )

    11.36 -0.18 (-1.56%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 448,251
    Open 11.61
    Bid (Size) 9.000 (1)
    Ask (Size) 11.79 (1)
    Prev. Close 11.54
    Today's Range 11.14 - 11.82
    52wk Range 7.210 - 16.88
    Shares Outstanding 34,233,643
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    -6.50%
    -6.50%
    1 Month
    -11.73%
    -11.73%
    3 Month
    -6.89%
    -6.89%
    6 Month
    +2.90%
    +2.90%
    1 Year
    +20.08%
    +20.08%

    More News

    Read More
    KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Appoints Brian Piekos as Chief Financial Officer
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024
    Via InvestorPlace
    KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.